Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Innate Pharma SA (OtherIPHYF)
Analysts fell to the sidelines weighing in on Alcon (ALC – Research Report) and Innate Pharma SA (IPHYF – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Confident Investing Starts Here:
Alcon (ALC)
Kepler Capital analyst Maja Pataki maintained a Hold rating on Alcon on May 13 and set a price target of CHF88.00. The company's shares closed last Wednesday at $87.24.
According to TipRanks.com, Pataki has 0 stars on 0-5 stars ranking scale with an average return of -13.6% and a 33.6% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Tecan Group AG, Demant, and Qiagen.
Currently, the analyst consensus on Alcon is a Strong Buy with an average price target of $110.11.
Innate Pharma SA (IPHYF)
Kepler Capital analyst Justine Telliez maintained a Hold rating on Innate Pharma SA on May 13 and set a price target of EUR3.10. The company's shares closed last Friday at $1.45, close to its 52-week low of $1.28.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
9 hours ago
- Business Insider
Kepler Capital Reaffirms Their Buy Rating on Banco Santander (BNC)
Kepler Capital analyst Jacques-Henri Gaulard maintained a Buy rating on Banco Santander (BNC – Research Report) on May 29 and set a price target of €8.10. The company's shares closed yesterday at p592.00. Confident Investing Starts Here: According to TipRanks, Gaulard is a 2-star analyst with an average return of 0.7% and a 43.48% success rate. Gaulard covers the Financial sector, focusing on stocks such as Banco Santander, BNP Paribas, and Societe Generale. In addition to Kepler Capital , Banco Santander also received a Buy from Morgan Stanley's Alvaro Serrano in a report issued on May 21. However, on May 29, J.P. Morgan maintained a Hold rating on Banco Santander (LSE: BNC). Based on Banco Santander's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of p33.75 billion and a net profit of p3.21 billion. In comparison, last year the company earned a revenue of p13.92 billion and had a net profit of p2.67 billion Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is neutral on the stock.
Business Insider
17 hours ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), 10x Genomics (TXG) and Kura Oncology (KURA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on scPharmaceuticals (SCPH – Research Report), 10x Genomics (TXG – Research Report) and Kura Oncology (KURA – Research Report). Confident Investing Starts Here: scPharmaceuticals (SCPH) Leerink Partners analyst Roanna Ruiz maintained a Buy rating on scPharmaceuticals on May 14 and set a price target of $11.00. The company's shares closed last Friday at $3.22. According to Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.1% and a 28.3% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Lexicon Pharmaceuticals, and Enanta Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for scPharmaceuticals with a $15.60 average price target, implying a 432.4% upside from current levels. In a report issued on May 12, Craig-Hallum also maintained a Buy rating on the stock. 10x Genomics (TXG) In a report issued on May 14, Puneet Souda from Leerink Partners maintained a Hold rating on 10x Genomics. The company's shares closed last Friday at $9.39, close to its 52-week low of $8.92. According to Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.4% and a 29.8% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. Currently, the analyst consensus on 10x Genomics is a Moderate Buy with an average price target of $12.56, a 36.2% upside from current levels. In a report issued on May 9, TD Cowen also maintained a Hold rating on the stock with a $11.00 price target. Kura Oncology (KURA) In a report issued on May 14, Jonathan Chang from Leerink Partners reiterated a Buy rating on Kura Oncology, with a price target of $23.00. The company's shares closed last Friday at $6.02. According to Chang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.0% and a 28.1% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Bicycle Therapeutics. Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $22.60, a 279.2% upside from current levels. In a report issued on May 1, TD Cowen also maintained a Buy rating on the stock.
Business Insider
19 hours ago
- Business Insider
Kepler Capital Keeps Their Sell Rating on NOS SGPS (0J1Z)
In a report released on May 29, Javier Borrachero from Kepler Capital maintained a Sell rating on NOS SGPS (0J1Z – Research Report), with a price target of €3.30. The company's shares closed last Thursday at €3.86. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Borrachero is a 4-star analyst with an average return of 5.9% and a 58.05% success rate. Borrachero covers the Communication Services sector, focusing on stocks such as Telecom Italia SPA, ORANGE SA, and Vodafone. The word on The Street in general, suggests a Strong Sell analyst consensus rating for NOS SGPS with a €3.57 average price target.
